Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds

@article{Faris1998EffectOO,
  title={Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds},
  author={Patricia L. Faris and Suck-Won Kim and William H. Meller and Robert L. Goodale and Randall D. Hofbauer and Scott A Oakman and Lynn A. Howard and Eric R Stevens and Elke D. Eckert and Boyd K. Hartman},
  journal={Pain},
  year={1998},
  volume={77},
  pages={297-303}
}
Abstract Thresholds for detection of both pressure and thermal pain are elevated in patients with bulimia nervosa. The present study was aimed at determining (1) if pressure pain detection thresholds (PDT) varied dynamically with the primary disease symptoms of binge eating and vomiting and (2) if the elevation in PDT was effected by treatment with ondansetron (ONDAN), a 5‐HT3 receptor antagonist. PDT was defined as the mean of the minimal amount of pressure (measured in g) perceived as painful… 
Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial
TLDR
The findings indicate a normalisation of the physiological mechanism(s) controlling meal termination and satiation in patients with severe bulimia nervosa in a randomised, double-blind, placebo-controlled study.
Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
TLDR
Reduction in IBS symptoms correlated with a drug-induced reduction in the activity of central autonomic networks mediating emotional expression that was maximal in the absence of nociceptive input.
Treatment of Bulimia Nervosa with Ondansetron
TLDR
Ondansetron for bulimia nervosa was reported to be effective in three small trials by one group of investigators, and may be an option after failure of traditional therapies.
A preliminary report on pain thresholds in bulimia nervosa during a bulimic episode.
TLDR
Pressure pain thresholds were assessed in nine subjects with bulimia nervosa on 3 consecutive days during a binge-eating and vomiting episode, during a normal meal, and after an overnight fast to show consistency with the hypothesis that vagal afferent activation by a B/V episode also activates the descending pain inhibitory pathway.
Pain perception in recovered bulimia nervosa patients.
  • D. Stein, W. Kaye, +5 authors R. Rao
  • Psychology, Medicine
    The International journal of eating disorders
  • 2003
TLDR
Investigating whether altered pain perception persists after recovery from bulimia nervosa (RBN) found women recovered from BN showed elevated pain threshold as measured with the submaximal effort tourniquet test (SETT) and a tendency to elevate pain threshold on the TPS.
Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms.
TLDR
Evidence from the laboratory that increases in vagal afferent activity are involved in perpetuating binge-eating and vomiting in bulimia nervosa is reviewed, suggesting that cyclic increases invagal activity drive the urge to binge-eat and vomit.
Alosetron and irritable bowel syndrome
TLDR
The most recent reported effects of alosetron on gastrointestinal motility, visceral sensitivity and anxiety, both in terms of preclinical and clinical data will be discussed.
De-stabilization of the positive vago-vagal reflex in bulimia nervosa
TLDR
A model for the pathophysiology of bulimia based upon de-stabilization of a bi-stable positive vago-vagal feedback loop is proposed to stimulate anatomical, psychobiological, and translational neuroscience experiments aimed at elucidating the patholympia and developing novel treatment strategies.
The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
TLDR
Antiinflammatory and immunomodulatory properties have been observed for 5-HT3-receptor antagonists which might explain promising findings in systemic sclerosis and other immunological conditions.
Current drug treatment of patients with bulimia nervosa and binge-eating disorder: selective serotonin reuptake inhibitors versus mood stabilizers
  • M. Bellini, M. Merli
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2004
TLDR
The aim was to review and compare findings from controlled trials and previous reviews concerning current drug treatment of patients suffering from bulimia nervosa and binge eating disorder, and Mood stabilizers are promising in this regard.
...
1
2
3
4
...

References

SHOWING 1-10 OF 39 REFERENCES
Treatment of bulimia nervosa with ondansetron.
TLDR
This hypothesis led us to treat a total of 5 women who met theDSM-III-Rcriteria for bulimia nervosa (binge-purge subtype) with ondansetron hydrochloride (a 5-hydroxytryptamine type 3 receptor antagonist that pharmacologically decreases vagal transmission), considered to have severe bulimic nervosa.
Pain perception in patients with eating disorders.
TLDR
Naloxone did not differ from placebo in its effect on the pain thresholds (phasic and tonic), suggesting that a nonopioid mechanism was responsible for the threshold elevation found in the eating disorder patients.
Dieting and pain sensitivity: A validation of clinical findings
TLDR
The reduced pain sensitivity in eating disorder patients is apparently not a mere effect of fasting, but a true pathological feature.
Mechanisms of vomiting induced by serotonin-3 receptor agonists in the cat: effect of vagotomy, splanchnicectomy or area postrema lesion.
The locations of serotonin-3 (5-HT3) receptors involved in initiating vomiting (emesis) were assessed by cutting visceral afferents or lesioning the area postrema. The 5-HT3 receptor agonists
Biological and behavioral responses to d-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers
TLDR
Results suggest that some but not most of D-amphetamine's biological and behavioral effects may be modified by a 5-HT3 antagonist in healthy human volunteers.
Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption.
TLDR
Serotonin uptake inhibitors and other serotonin-altering medications are promising new neuropharmacological treatments for reducing AC and may be suitable pharmacological adjuncts in relapse prevention strategies.
Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption.
TLDR
Serotonin uptake inhibitors and other serotonin-altering medications are promising new neuropharmacological treatments for reducing AC and may be suitable pharmacological adjuncts in relapse prevention strategies.
Pain sensitivity and obesity
TLDR
The difference in pain sensitivities supports the hypothesis that the weight difference between the obese and nonobese subjects may be related to endogenous opiate control of ingestive behaviors.
Pain sensitivity in anorexia nervosa and bulimia nervosa
TLDR
Pain threshold correlated significantly (negatively) with local skin temperature in the anorectic patients and almost significantly (positively) with body weight in the bulimic patients, suggesting that the reduced pain in the two kinds of eating disorders might have different causes.
Pain sensitivity, alexithymia, and depression in patients with eating disorders: are they related?
TLDR
Thresholds to thermally induced pain in patients with anorexia or bulimia were similar and significantly higher than in the healthy subjects, while Alexithymia and depression scores were significantly higher in anorexic and bulimic patients than inThe healthy subjects.
...
1
2
3
4
...